FibroGen Inc - FGEN Earnings per share for the trailing year
FibroGen, Inc. (FGEN) is facing a critical capital shortage and the threat of insolvency due to past trial failures. This daily price chart for the security with the 231.80 indicator illustrates the financial condition of the innovator developing drugs to combat fibrosis and hypoxia. The company is currently undergoing a rigorous internal restructuring, cutting costs and attempting to find new allies to sustain its operations.
%20FibroGen&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_FGEN_-_FibroGen-Inc._-_Net-earnings-per-share-EPS-TTM "FGEN (FibroGen, Inc.) Net earnings per one share for the last twelve months history from 02/11/2024 to 01/08/2026 | 👁️GURU.Markets👁️")
fibrogen.com - analytical breakdowns and key metrics (FGEN)
- stock price and consensus target price:
- issuer market value details:
- issuer book value statistics:
- company total debt and liquidity indicators:
Aggregate Debt to Equity FibroGen, Inc.|FGEN - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient FibroGen, Inc.|FGEN - Company Aggregate Debts|Debt to Book Capitalization Ratio FibroGen Corporation|FGEN - Company Long-Term Debt|Company Short-Term Loans and Borrowings FibroGen|Immediate Liquidity fibrogen.com
- net income and valuation ratios data:
FGEN - Net Profit|Projected Net Profit FibroGen, Inc.|FGEN - P/E Multiple|Projected Price to Earnings Ratio FibroGen Corporation|FGEN - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation FibroGen|FGEN - Operating profit before deduction of amortization|Earnings per share for the trailing year FibroGen|FGEN - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months fibrogen.com|FGEN - Earnings per share growth in current year|Projected earnings per share growth rate for next year FibroGen, Inc.
- revenue and sales details:
Fundamental company valuation:FibroGen Inc - FGEN
FibroGen, Inc. (FGEN) focus on fibrosis research, while delegating production and logistics to external contractors, makes its cost structure dependent on outsourcing efficiency. The year-over-year earnings per share dynamics reflect the actual sensitivity of this model to market shocks, and the annual shift in EPS TTM allows for an assessment of investment safety and the avoidance of overpayment by eliminating the time lags of standard reporting.
Competitor analysis
Earnings per share for the trailing year HLN (Haleon)|KVUE: Net earnings per share (EPS TTM)|Verona Pharma Corp - Earnings per share for the trailing year|MENS (Jyong Biotech Limited) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months ligand.com LGND|Earnings per share for the last twelve months Amneal (AMRX)|PRGO (Perrigo Company PLC) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) ALVO (Alvotech S.A.)|Liquidia Technologies - Earnings per share for the last twelve months|Galapagos Corp - Net earnings per share (EPS TTM)|ANIP (ANI Pharmaceuticals) - Earnings per share for the last 12 months|MannKind Corp. (MNKD) - Earnings per share for the last twelve months|Earnings per one share for the last 12 months AMPH (Amphastar Pharmaceuticals, Inc.)|PCRX (Pacira Corp) - Net earnings per share (EPS TTM)|SPRY: Earnings per share for the trailing year|Net earnings per share (EPS TTM) TBPH|Net earnings per share for the last four quarters Aquestive Therapeutics, Inc.|Earnings per share for the last twelve months scPharmaceuticals Inc. SCPH|TECX: Earnings per share for the last 12 months|TNXP - Earnings per share for the last twelve months|Net earnings per share for the last four quarters SXT Pharmaceuticals SXTC|EPRX: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months bioharvest.com (BHST)|Net earnings per share for the last 12 months EXOZ|ORMP: Earnings per share for the trailing year|Earnings per share for the last twelve months Entera Bio Ltd. (ENTX)|HYFT (MindWalk Therapeutics) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) ABVC (ABVC BioPharma, Inc)|Earnings per share for the trailing year CPIX|QNTM - Earnings per share for the last twelve months|Earnings per share for the trailing year TELO (Telomir Pharmaceuticals Inc)|RANI (Rani Therapeutics Holdings, Inc.) - Net earnings per share for the last 12 months|Net earnings per share for the last 12 months Synergy CHC Corporation|Earnings per share for the last twelve months Rallybio Corp|Lexaria Bioscience (LEXX) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Pulmatrix, Inc. (PULM)|Net earnings per share for the last four quarters Pheton|Earnings per share for the last twelve months Aptorum Group Limited APM|LYRA - Net earnings per share for the last 12 months|IBO: Net earnings per share for the last 12 months|TNFA - Net earnings per share (EPS TTM)|cbdMD Corp (YCBD) - Earnings per share for the last twelve months|Earnings per one share for the last 12 months PRFX (PainReform Limited)|CYTO (Altamira Therapeutics Ltd.) - Net earnings per share (EPS TTM)|Lipella (LIPO) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) OPTN|Net earnings per share (EPS TTM) pieris.com (PIRS)|Earnings per share for the last twelve months Procaps Group Corp PROC|Petros Pharmaceuticals Inc - Earnings per share for the last twelve months|Qilian International Corp - Net earnings per share (EPS TTM)|ACELYRIN, Inc. (SLRN) - Net earnings per share for the last 12 months|TFF Pharma (TFFP) - Earnings per share for the last twelve months
